XML 103 R89.htm IDEA: XBRL DOCUMENT v3.24.3
LEGAL PROCEEDINGS - Intellectual Property (Details)
1 Months Ended 9 Months Ended
Oct. 30, 2024
proceeding
Oct. 01, 2024
Sep. 27, 2024
Sep. 18, 2024
Jun. 20, 2024
Apr. 05, 2024
Sep. 10, 2021
Feb. 17, 2020
Oct. 31, 2023
Jan. 31, 2023
Apr. 30, 2021
Mar. 31, 2021
defendant
proceeding
Sep. 30, 2024
proceeding
Norwich I Xifaxan Litigation                          
Loss Contingencies [Line Items]                          
Loss contingency, stay of approval, period               30 months 30 months 30 months      
Norwich II Xifaxan Litigation                          
Loss Contingencies [Line Items]                          
Gain contingency, stay of approval, period         30 months                
Amneal Xifaxan Litigation                          
Loss Contingencies [Line Items]                          
Gain contingency, stay of approval, period           30 months              
Zydus Xifaxan Litigation                          
Loss Contingencies [Line Items]                          
Gain contingency, stay of approval, period     30 months                    
Cipla Anticipated Xifaxan Litigation                          
Loss Contingencies [Line Items]                          
Loss contingency, stay of approval, period       30 months                  
Carnegie Anticipated Xifaxan Litigation | Subsequent Event                          
Loss Contingencies [Line Items]                          
Loss contingency, stay of approval, period   30 months                      
MSN Laboratories Private Ltd. Litigation                          
Loss Contingencies [Line Items]                          
Gain contingency, stay of approval, period                     30 months    
PreserVision® AREDS Patent Litigation | Settled Litigation | Bausch + Lomb                          
Loss Contingencies [Line Items]                          
Number of defendants                         13
PreserVision® AREDS Patent Litigation | Default Judgement | Bausch + Lomb                          
Loss Contingencies [Line Items]                          
Number of defendants                         2
PreserVision® AREDS Patent Litigation | Pending Litigation | Bausch + Lomb                          
Loss Contingencies [Line Items]                          
Number of defendants | defendant                       20  
Number of proceedings                       17  
PreserVision® AREDS Patent Litigation | Pending Litigation | Bausch + Lomb | Subsequent Event                          
Loss Contingencies [Line Items]                          
Number of defendants 2                        
Lumify Paragraph I V Proceedings Slayback ANDA Litigation | Bausch + Lomb                          
Loss Contingencies [Line Items]                          
Loss contingency, stay of approval, period             30 months